KRAS and PIK3CA mutations occur concomitantly in approximately 10%-12% of CRC and are significantly associated (p-value < 0.001; data retrieved from cBioportal (www.cbioportal.org); (48, 49), indicating that the findings described here might be relevant for a significant fraction of CRC patients, considered resistant to currently available treatments. This evidence concerns the gene KRAS and colorectal carcinoma.